Organogenesis Holdings Inc. (NASDAQ:ORGO) Insider Lori Freedman Buys 142,379 Shares

Organogenesis Holdings Inc. (NASDAQ:ORGO - Get Free Report) insider Lori Freedman purchased 142,379 shares of the firm's stock in a transaction that occurred on Thursday, June 5th. The shares were acquired at an average cost of $2.91 per share, for a total transaction of $414,322.89. Following the purchase, the insider now owns 837,437 shares of the company's stock, valued at $2,436,941.67. This represents a 20.48% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Lori Freedman also recently made the following trade(s):

• On Friday, June 6th, Lori Freedman acquired 9,022 shares of Organogenesis stock. The shares were bought at an average price of $2.99 per share, for a total transaction of $26,975.78.
• On Wednesday, June 4th, Lori Freedman acquired 100,863 shares of Organogenesis stock. The shares were bought at an average price of $2.82 per share, for a total transaction of $284,433.66.

Organogenesis Trading Up 13.5%

ORGO stock traded up $0.41 during midday trading on Monday, reaching $3.44. 2,247,351 shares of the company traded hands, compared to its average volume of 1,150,852. Organogenesis Holdings Inc. has a 52-week low of $2.28 and a 52-week high of $6.71. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. The business has a 50 day moving average of $3.82 and a 200-day moving average of $3.85. The firm has a market capitalization of $436.38 million, a price-to-earnings ratio of -57.33 and a beta of 1.63.

Organogenesis (NASDAQ:ORGO - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.17). Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. The company had revenue of $86.69 million for the quarter, compared to analysts' expectations of $90.77 million. As a group, sell-side analysts expect that Organogenesis Holdings Inc. will post -0.07 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Morgan Stanley upped their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Institutional Investors Weigh In On Organogenesis

Several hedge funds and other institutional investors have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Organogenesis by 10.8% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 43,398 shares of the company's stock worth $187,000 after buying an additional 4,239 shares during the period. CWM LLC increased its stake in Organogenesis by 8.9% in the 1st quarter. CWM LLC now owns 63,894 shares of the company's stock worth $276,000 after buying an additional 5,239 shares during the period. Millennium Management LLC increased its stake in Organogenesis by 2.8% in the 4th quarter. Millennium Management LLC now owns 208,420 shares of the company's stock worth $667,000 after buying an additional 5,765 shares during the period. ProShare Advisors LLC increased its stake in Organogenesis by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after buying an additional 6,689 shares during the period. Finally, Rhumbline Advisers increased its stake in Organogenesis by 7.1% in the 4th quarter. Rhumbline Advisers now owns 115,266 shares of the company's stock worth $369,000 after buying an additional 7,621 shares during the period. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.